World's Best Scientists 2026 revealed!
John H. Sampson

John H. Sampson

D-Index & Metrics

Medicine

D-Index
111
Citations
41987
World Ranking
5363
National Ranking
2892

Research.com Recognitions

  • 2017 - Member of the National Academy of Medicine (NAM)
  • 1951 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John H. Sampson is affiliated with Duke University in the United States and has an extensive research portfolio primarily in medicine and immunology and microbiology. Their work spans various subfields including immunology, oncology, genetics, molecular biology, and biotechnology.

Their main areas of research focus on topics such as:

  • Glioma Diagnosis and Treatment
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • Immune cells in cancer
  • RNA Interference and Gene Delivery

They have contributed to several frequently published venues, including:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Neuro-Oncology Advances
  • Cancer Research

Selected recent papers authored or co-authored by John H. Sampson include:

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020, JAMA Oncology)
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial (2020, Clinical Cancer Research)
  • Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement (2021, Clinical Cancer Research)
  • PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? (2020, Clinical Cancer Research)
  • Current multidisciplinary management of brain metastases (2020, Cancer)

Frequent collaborators in their research include:

  • Mustafa Khasraw
  • Kelly Hotchkiss
  • David M. Ashley
  • James E. Herndon
  • Annick Desjardins

John H. Sampson has been recognized by professional organizations with memberships and fellowships, including:

  • Member of the National Academy of Medicine (NAM) since 2017
  • Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians

Best Publications

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

    David A. Reardon;Alba A. Brandes;Antonio Omuro;Paul Mulholland

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • Challenges to curing primary brain tumours

    Kenneth Aldape;Kevin M Brindle;Louis Chesler;Rajesh Chopra

  • Brain immunology and immunotherapy in brain tumours

    John H. Sampson;Michael D. Gunn;Peter E. Fecci;David M. Ashley

  • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

    Peter E. Fecci;Duane A. Mitchell;John F. Whitesides;Weihua Xie

  • Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma

    John H. Sampson;James H. Carter;Allan H. Friedman;Hilliard F. Seigler

  • Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

    Pakawat Chongsathidkiet;Christina Jackson;Shohei Koyama;Franziska Loebel

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • Proteomic and immunologic analyses of brain tumor exosomes

    Michael W. Graner;Oscar Alzate;Angelika M. Dechkovskaia;Jack D. Keene

  • Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

    Sandeep Kunwar;Susan Chang;Manfred Westphal;Michael Vogelbaum

  • Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

    Antonio Omuro;Gordana Vlahovic;Michael Lim;Solmaz Sahebjam

  • Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

    Duane A. Mitchell;Weihua Xie;Robert Schmittling;Chris Learn

  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    James Schuster;Rose K. Lai;Rose K. Lai;Lawrence D. Recht;David A. Reardon;David A. Reardon

  • Prospects of immune checkpoint modulators in the treatment of glioblastoma.

    Matthias Preusser;Michael Lim;David A. Hafler;David A. Reardon

  • OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

    D. A. Reardon;A. Omuro;A. A. Brandes;J. Rieger;J. Rieger

  • Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

    David A. Reardon;Gamal Akabani;R. Edward Coleman;Allan H. Friedman

Frequent Co-Authors

Darell D. Bigner
Darell D. Bigner Duke University
James E. Herndon
James E. Herndon Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Henry S. Friedman
Henry S. Friedman Duke University
David A. Reardon
David A. Reardon Harvard University
Gary E. Archer
Gary E. Archer Duke University
Roger E. McLendon
Roger E. McLendon Duke University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Smita Nair
Smita Nair Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your medical education beyond a traditional MD program can open new doors in healthcare. Many students are now exploring 1 year dnp program online options to quickly advance in nursing leadership roles. These programs offer greater flexibility for working professionals.

If you’re interested in the pharmaceutical field, online pharmd programs provide a pathway to becoming a pharmacist without sacrificing your current commitments. These accredited degrees allow you to balance work and study, making it easier to upskill or change careers.

For high school students interested in healthcare, the best online schools for high school students can provide early access to courses in medicine, health management, and science, which helps build a strong foundation before entering college-level programs.

Those considering administrative roles may also ask, how much does it cost to become a medical coder? Fortunately, affordable online medical billing and coding courses make this career accessible and cost-effective for many, with the added benefit of being able to study at your own pace.

Best Scientists Citing John H. Sampson

Trending Scientists

Recently Published Articles